Development of a Highly Potent Neurokinin‑3 Receptor Inhibitor: Design, Synthesis, and Evaluation

Area of Science:

• Medicinal Chemistry
• Pharmacology

Background:

• The neurokinin-3 receptor (NK3R) is a key target for managing conditions like hot flashes.
• Current NK3R antagonist options are limited, highlighting the need for new therapeutic agents.

Purpose of the Study:

• To design and synthesize novel imidazole-piperazine derivatives as potential NK3R antagonists.
• To evaluate the efficacy and pharmacokinetic properties of these novel compounds.

Main Methods:

• Rational drug design and chemical synthesis of imidazole-piperazine derivatives.
• Molecular docking studies to predict target binding.
• In vitro assessment of NK3R inhibitory activity and membrane permeability.
• In vivo studies to evaluate oral bioavailability and efficacy (luteinizing hormone suppression).

Main Results:

• A series of novel imidazole-piperazine derivatives (compounds 13a-13l, 17a-17f, 22a-22i) were successfully synthesized.
• Compound 22i demonstrated potent NK3R binding and inhibitory activity, validated by molecular docking.
• Compound 22i exhibited favorable membrane permeability and high oral bioavailability.
• In vivo studies confirmed that oral administration of 22i effectively suppressed luteinizing hormone levels.

Conclusions:

• The synthesized imidazole-piperazine derivatives represent promising candidates for NK3R antagonism.
• Compound 22i shows significant potential as a therapeutic agent for conditions mediated by neurokinin B signaling, warranting further development.